Advertisement TRACON modifies license deal with Case Western Reserve University - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

TRACON modifies license deal with Case Western Reserve University

US-based TRACON Pharmaceuticals (TCON) has entered into an amended license agreement and a new sponsored research collaboration with Case Western Reserve University (CWRU).

TCON is focused on the development and commercialization of new targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases.

The agreement strengthens intellectual property estate around TRC102 by including additional issued patents and patent applications covering combinations of TRC102 with certain approved chemotherapeutic agents.

It will also see patents covering the use of biomarkers that may be used to predict which patients are most likely to respond to TRC102 treatment.

Additionally, the two parties have entered into a sponsored research agreement whereby CWRU will further assess biomarkers that may predict the activity of regimens combining TRC102 with chemotherapeutics, including Alimta (pemetrexed).

TRACON president and CEO Charles Theuer said: "We are happy to expand our productive partnership with Case Western Reserve University and look forward to their continued support of our TRC102 clinical development program.

"We believe that this partnership, along with our collaboration with the National Cancer Institute, will help maximize TRC102’s potential to reverse resistance to chemotherapy, a characteristic that could improve outcomes of patients with lung cancer, brain cancer as well as other malignancies."

TRC102 is a new clinical stage small molecule inhibitor of the DNA base excision repair pathway that causes resistance to alkylating and antimetabolite chemotherapeutics.

Currently, TRC102 is being evaluated in clinical trials sponsored by both the National Cancer Institute and Case Comprehensive Cancer Center.